Digital Therapeutics (DTx) are evidence-based therapeutic interventions delivered as mobile software applications. They undergo rigorous clinical and regulatory review, ensuring the same high standards of efficacy and safety as with traditional drugs. A DTx can be prescribed by a physician alongside a drug or therapy or as a stand-alone treatment.
Eila® is a 12-week program for the treatment of tobacco dependence. The DTx is currently undergoing clinical trial in Germany to provide an evidence-based, clinically validated, and personalized digital therapy to patients.
In collaboration with:
The comprehensive DTx will provide treatment for currently undertreated symptoms associated with PF, such as low mood and anxiety, improving the patient's quality of life.
In collaboration with:
With a patient-centric mentality, we are driven by our goal of delivering targeted personalized care. Our novel DTx treatments are developed in collaboration with patient groups and deliver targeted, personalized care to patients with overlooked symptoms.
